Entyvio for Crohn's Disease

ENTYVIO made remission real for many people with moderate to severe Crohn's disease

Patient Portrayal

In three clinical trials, ENTYVIO infused intravenously delivered results for adult patients with moderate to severe Crohn's disease when other medicines had not worked well enough or could not be tolerated.

The first and second studies evaluated the number of patients who achieved remission on ENTYVIO versus placebo at Week 6; additionally, the second study also evaluated remission at Week 10. The third study enrolled adults who had a previous response to ENTYVIO at Week 6 and evaluated remission at Week 52.

Results with IV infusion were seen as early as 6 weeks

ENTYVIO helped


as many people
achieve remission vs placebo

At 6 weeks of treatment, 15% of people on ENTYVIO achieved remission* compared to 7% of people on placebo.

Long-term remission

ENTYVIO helped


people achieve remission
at 1 year vs placebo

39% of people on ENTYVIO achieved remission* at 1 year of treatment, compared to 22% of people on placebo.


  • Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients.
  • ENTYVIO may cause serious side effects, including:
    • Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. You may need treatment if you have an allergic reaction. Tell your healthcare provider or get immediate medical help if you get any of these symptoms during or after an infusion of ENTYVIO: rash, itching, swelling of your lips, tongue, throat, or face, shortness of breath or trouble breathing, wheezing, dizziness, feeling hot, or palpitations (feeling like your heart is racing).

Please see additional Important Safety Information below.

Results without steroids

ENTYVIO helped


people achieve remission without depending on steroids vs placebo

32% of people on ENTYVIO achieved remission without the use of steroids at 1 year compared to 16% of people on placebo.

Some patients were on steroids at the beginning of the study. ENTYVIO helped some of these patients achieve remission without the use of steroids at Week 52.

Remission with the ENTYVIO Pen


helped more people achieve
remission at 1 year vs placebo

A separate clinical study evaluated remission at Week 52 in adult patients with moderate to severe Crohn’s who were administered ENTYVIO subcutaneously compared to placebo.

48% of people administered ENTYVIO subcutaneously achieved remission at 1 year of treatment compared to 34% of people on placebo.

*Remission is a measure to determine when a patient with Crohn's is experiencing a few to no symptoms and an improvement in their condition.

In the ENTYVIO clinical studies, clinical remission was defined and measured by improvement in the CDAI score, a tool that assesses the number of liquid or very soft stools, abdominal pain, and other measures of disease activity.

Ask your doctor if ENTYVIO is right for you.

Sign up for EntyvioConnect

Ready to access everything EntyvioConnect has to offer? Sign up today!

Sign up

What's it like to take ENTYVIO?

Questions about taking ENTYVIO? Here's how it works.

Learn more